Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies.
DNA of 258 patients with treatment-resistant depression was collected in three 8-10 week, two-arm, prospective clinical trials. Forty-four allelic variations were measured in genes for the cytochrome P450 (CYP) enzymes CYP2D6, CYPC19, and CYP1A2, the serotonin transporter (SLC6A4), and the 5-HT2A receptor (HTR2A). The combinatorial pharmacogenomic (CPGx™) GeneSight test results were provided to clinicians to support medication changes from baseline (guided arm), or they were provided at the end of each study to clinicians of unguided patients who were treated as usual (TAU). TAU subjects who at baseline were prescribed medications genetically discordant for them showed only a 12% symptom improvement, far less than the 32.5% or 28.5% improvements of the TAU subjects on yellow-category ('use with caution'; p = 0.002) or green-category medications ('use as recommended'; p = 0.02), respectively. The odds of a clinical response were increased 2.3-fold among all GeneSight-guided compared to all TAU subjects (p = 0.004), and overall, the guided group had a 53% greater improvement in depressive symptoms (p = 0.0002), a 1.7-fold relative improvement in response (p = 0.01), and a number needed to treat for one clinical response above that seen in the TAU group of 6.07.
AssureRx Health, Inc., Mason, Ohio, USA.
C Anthony
CA
Altar
AssureRx Health, Inc., Mason, Ohio, USA.
Joseph
J
Carhart
AssureRx Health, Inc., Mason, Ohio, USA.
Josiah D
JD
Allen
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minn., USA.
Daniel
D
Hall-Flavin
AssureRx Health, Inc., Mason, Ohio, USA; Winner Psychiatry, Boulder, Colo., USA.
Joel
J
Winner
AssureRx Health, Inc., Mason, Ohio, USA.
Bryan
B
Dechairo
Allele; Anxiety; Combinatorial pharmacogenomics; Depression; Genomics; Polymorphism; Psychiatry; Translational medicine